<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652080</url>
  </required_header>
  <id_info>
    <org_study_id>CTL0408</org_study_id>
    <nct_id>NCT00652080</nct_id>
  </id_info>
  <brief_title>An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berg, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Berg, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of pharmaceutical
      compound 31510 in a topical cream when applied to in situ cutaneous squamous cell carcinoma
      and to obtain preliminary efficacy data for the treatment of in situ cutaneous squamous cell
      carcinoma by Compound 31510 topical cream.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the safety and tolerability of API 31510 cream 3%, topically applied to in situ cutaneous squamous cell carcinomas (SCCIS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Complete Response</measure>
    <time_frame>6 weeks</time_frame>
    <description>To obtain a preliminary determination of the efficacy of API 31510 cream 3%,topically applied to in situ cutaneous squamous cell carcinomas.
The subject was considered to have had a complete response only if the histological examination of the target lesion was negative.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Cream 3%; AM &amp; PM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>API 31510</intervention_name>
    <description>Topical Cream; 3% active; AM &amp; PM application</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults &gt; 18 years of age

          -  Primary, histologically confirmed SCCIS with a minimum area of 0.5 cm2 and with a
             maximum diameter of 2.0 cm target SCCIS lesion suitable for excision

          -  Histological diagnosis made no more than 4 weeks prior to the screening visit

          -  Histological biopsy removed 25% or less of the target lesion

          -  No other dermatological disease in the SCCIS target site or surrounding area

          -  Willing to refrain from using non-approved lotions or creams on the target site and
             surrounding area during the treatment period. Willing to refrain from washing the
             treated area for at least 8 hours following the application of study medication

          -  Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid
             the use of tanning parlors for the duration of the study

          -  Laboratory values for the tests listed in the Study Schedule on page 2 within the
             reference ranges as defined by the central laboratory, or &quot;out of range&quot; test results
             that are clinically acceptable to the investigator.

          -  Ability to follow study instructions and likely to complete all study requirements

          -  Written informed consent obtained, including consent for tissue to be examined and
             stored by the central dermatopathologist.

          -  Written consent to allow photographs of the target SCCIS lesion to be used as part of
             the study data

          -  For females of childbearing potential, a negative pregnancy test at screening and
             using an acceptable form of birth control (oral/implant/injectable/transdermal
             contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous
             relationship with a partner who has had a vasectomy)

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Presence of known or suspected systemic cancer

          -  Histological evidence of nBCC, sBCC, or any other tumor in the biopsy specimen

          -  Histological evidence of severe squamous metaplasia, infiltrative, desmoplastic or
             micronodular growth patterns in the biopsy specimen

          -  History of recurrence of the target SCCIS lesion

          -  Evidence of dermatological disease or confounding skin condition in the treatment
             area, e.g., BCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema,
             xeroderma pigmentosa

          -  Concurrent disease or treatment that suppresses the immune system

          -  Chronic medical condition that in the judgment of the investigator(s) would interfere
             with the performance of the study or would place the patient at undue risk

          -  Known sensitivity to any of the ingredients in the study medication

          -  Use of a tanning parlor or other excessive or prolonged exposure to ultraviolet light
             or direct sunlight during the course of the study

          -  Treatment with systemic chemotherapeutic agents within the 6 months prior to the
             screening visit

          -  Use of systemic retinoids within the 6 months prior to the screening period

          -  Treatment with systemic immunomodulators or immunosuppressants within the 6 months
             prior to the screening period

          -  Use of topical immunomodulators within 2 cm of the target SCCIS lesion within the 4
             weeks prior to the screening period

          -  Treatment with the following topical agents within the 4 weeks prior to the screening
             visit; levulinic acid, 5-fluorouracil, corticosteroids, retinoids, diclofenac,
             hyaluronic acid, imiquimod

          -  Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing,
             dermabrasion, within the 6 months prior to the screening visit, if the target SCCIS
             lesion is on the face

          -  Treatment with liquid nitrogen, surgical excision or curettage within 2cm of the
             target SCCIS lesion during the 4 weeks prior to the screening visit

          -  Elective surgery within 4 weeks prior to the screening visit, during the study, or 4
             weeks after the treatment period

          -  Evidence of current chronic alcohol or drug abuse

          -  Current enrollment in an investigational drug or device or participation in such a
             study within 4 weeks of the screening visit

          -  In the investigator's opinion, evidence of unwillingness, or inability to follow the
             restrictions of the protocol and complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Burke Pharmaceuticals</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Surgery Medical Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glazer Dermatology</name>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <zip>60089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Skin Cancer and Dermatalogic Surgery, PC</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Education and Research Foundation</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>April 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <results_first_submitted>January 22, 2019</results_first_submitted>
  <results_first_submitted_qc>January 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects were required to have at least one histologically-confirmed SCCIS lesion that was suitable for excision, ie, to have a lesion with a minimum area of 0.5 cm2 and a maximum diameter of 2.0 cm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>API 31510 Topical Cream</title>
          <description>Active Cream 3%; AM &amp; PM
API 31510: Topical Cream; 3% active; AM &amp; PM application</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>API 31510 Topical Cream</title>
          <description>Active Cream 3%; AM &amp; PM
API 31510: Topical Cream; 3% active; AM &amp; PM application</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>To determine the safety and tolerability of API 31510 cream 3%, topically applied to in situ cutaneous squamous cell carcinomas (SCCIS).</description>
        <time_frame>6 weeks</time_frame>
        <population>Safety Population: All subjects who took at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Active Cream 3%; AM &amp; PM
API 31510: Topical Cream; 3% active; AM &amp; PM application</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>To determine the safety and tolerability of API 31510 cream 3%, topically applied to in situ cutaneous squamous cell carcinomas (SCCIS).</description>
          <population>Safety Population: All subjects who took at least one dose of the investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects with an AE (Mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects with an AE (Moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects with an AE (Severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects without an AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Complete Response</title>
        <description>To obtain a preliminary determination of the efficacy of API 31510 cream 3%,topically applied to in situ cutaneous squamous cell carcinomas.
The subject was considered to have had a complete response only if the histological examination of the target lesion was negative.</description>
        <time_frame>6 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All subjects who were dispensed the study drug were included in this population.
Per Protocol (PP) Population: All subjects who had SCCIS confirmed via histological results at baseline, had a Week 6 histological examination, and did not miss any interim visits.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Population</title>
            <description>Active Cream 3%; AM &amp; PM
API 31510: Topical Cream; 3% active; AM &amp; PM application</description>
          </group>
          <group group_id="O2">
            <title>PP Population</title>
            <description>Active Cream 3%; AM &amp; PM
API 31510: Topical Cream; 3% active; AM &amp; PM application</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Complete Response</title>
          <description>To obtain a preliminary determination of the efficacy of API 31510 cream 3%,topically applied to in situ cutaneous squamous cell carcinomas.
The subject was considered to have had a complete response only if the histological examination of the target lesion was negative.</description>
          <population>Intent-to-Treat (ITT) Population: All subjects who were dispensed the study drug were included in this population.
Per Protocol (PP) Population: All subjects who had SCCIS confirmed via histological results at baseline, had a Week 6 histological examination, and did not miss any interim visits.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All subjects in this study were treated with a formulation of CoQ10 3% topical cream that was applied twice daily for 6 weeks. The mean duration (SD) of treatment was 41.4 days (6.7) and ranged from 21 to 47 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Safety Population</title>
          <description>Active Cream 3%; AM &amp; PM
API 31510: Topical Cream; 3% active; AM &amp; PM application</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nathaniel DiTommaso</name_or_title>
      <organization>Berg LLC</organization>
      <phone>617-588-1002</phone>
      <email>nate.ditommaso@berghealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

